(E)-Alprenoxime structure
|
Common Name | (E)-Alprenoxime | ||
---|---|---|---|---|
CAS Number | 125720-84-5 | Molecular Weight | 262.34700 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C15H22N2O2 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of (E)-Alprenoxime(E)-Alprenoxime is the isomer of the Alprenoxime. Alprenoxime is a site-activated ocular β-blocker. |
Name | 1-(2-Allyl-phenoxy)-3-isopropylamino-propan-2-one oxime |
---|---|
Synonym | More Synonyms |
Description | (E)-Alprenoxime is the isomer of the Alprenoxime. Alprenoxime is a site-activated ocular β-blocker. |
---|---|
Related Catalog | |
Target |
β blocker[1] |
In Vivo | The purpose of the present study is to explore the pharmacological significance of Alprenoxime peripheral /βblocking activity in a non-rodent animal model. Interspecies scaling considerations predict that the doses selected in this study (1 and 5 mg/kg) are pharmacologically comparable or greater than doses used in rodent studies (2 and 6 mg/kg). More importantly, the prolonged ocular antihypertensive effects that are shown with 1% ophthalmic solutions indicate that the i.v. dose tested in the present study is likely to be more than two orders of magnitude greater than probable therapeutic doses[1]. |
Animal Admin | Dogs[1] Seven adult mongrel dogs (20-27 kg) are used in this study. A loading dose of Alprenoxime is administered (1 mg/kg, i.v.) followed by Alprenoxime infusion (150 μg/kg/min) after recording baseline electrophysiological parameters. Cardiac electrophysiological testing is then repeated 10 min after beginning Alprenoxime infusion. Alprenoxime (1 or 5 mg/kg, i.v.) is injected as a bolus injection and cardiac electrophysiological response is monitored. Different dogs with isoproterenol induced tachycardia are evaluated at each Alprenoxime dose. |
References |
Molecular Formula | C15H22N2O2 |
---|---|
Molecular Weight | 262.34700 |
Exact Mass | 262.16800 |
PSA | 53.85000 |
LogP | 3.01300 |
(E)-Alprenoxime |